A Phase I, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STSA-1005 Following Intravenous Infusion in Healthy Subjects
Latest Information Update: 20 Apr 2022
Price :
$35 *
At a glance
- Drugs STSA-1005 (Primary)
- Indications Autoimmune disorders; COVID 2019 infections
- Focus Adverse reactions
- Sponsors Staidson Biopharma
- 14 Apr 2022 Status changed from recruiting to completed.
- 27 Oct 2021 Status changed from not yet recruiting to recruiting.
- 27 Oct 2021 New trial record